THE ROLE OF BASELINE CONCOMITANT USE OF CONVENTIONAL SYNTHETIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS WITH TNF INHIBITORS IN SPONDYLOARTHRITIS PATIENTS

被引：0

作者：

Akar, S. ^{[1
]}

Kiraz, S. ^{[2
]}

Gercik, O. ^{[1
]}

Ertenli, I. ^{[2
]}

Kucuksahin, O. ^{[2
]}

Dalkilic, E. ^{[3
]}

Bes, C. ^{[4
]}

Kasifoglu, T. ^{[5
]}

Emmungil, H. ^{[6
]}

Koca, S. S. ^{[7
]}

Cinar, M. ^{[2
]}

Yazisiz, V. ^{[8
]}

Dincer, B. Kelesoglu ^{[2
]}

Ates, A. ^{[2
]}

Kanitez, N. Alpay ^{[4
]}

Erten, S. ^{[2
]}

Turan, S. ^{[6
]}

Pehlivan, Y. ^{[3
]}

Oz, B. ^{[7
]}

Bilge, S. Yasar ^{[5
]}

Erden, A. ^{[2
]}

Armagan, B. ^{[2
]}

Coskun, B. N. ^{[3
]}

Kalyoncu, U. ^{[2
]}

机构：

[1] TURKBIO Biol Registry, Izmir, Turkey

[2] TReasure Biol Registry, Ankara, Turkey

[3] TReasure Biol Registry, Bursa, Turkey

[4] TReasure Biol Registry, Istanbul, Turkey

[5] TReasure Biol Registry, Eskisehir, Turkey

[6] TReasure Biol Registry, Edirne, Turkey

[7] TReasure Biol Registry, Elazig, Turkey

[8] TReasure Biol Registry, Antalya, Turkey

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷

关键词：

D O I：

10.1136/annrheumdis-2018-eular.4646

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

SAT0297

引用

页码：1012 / 1013

页数：2

共 50 条

[1] Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs and the Risk of Vascular Dementia in Patients with Spondyloarthritis: A Database Cohort Study
Lee, Yu-Hao
Huang, Shih-Wei
Chen, Chih-Kuang
Hong, Jia-Pei
Chen, Yi-Wen
Lin, Hui-Wen
JOURNAL OF CLINICAL MEDICINE, 2023, 12 (03)
[2] Malignancies in spondyloarthritis with and without concomitant psoriasis, and the effect of disease-modifying anti-rheumatic drugs
Chung, H. Y.
Chan, S. C. W.
Chui, E. T. F.
Yau, T.
Lau, C. S.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2022, 40 (05) : 913 - 920
[3] The use of conventional disease-modifying anti-rheumatic drugs in established RA
Jurgens, M. S.
Jacobs, J. W. G.
Bijlsma, J. W. J.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2011, 25 (04): : 523 - 533
[4] GUIDELINE ON CONVENTIONAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
Galloway, James
RHEUMATOLOGY, 2016, 55 : 14 - 14
[5] DISEASE MODIFYING ANTI-RHEUMATIC DRUGS
STECHER, VJ
CARLSON, JA
ANNUAL REPORTS IN MEDICINAL CHEMISTRY, 1983, 18 : 171 - 179
[6] SYSTEMATIC REVIEW OF LABORATORY MONITORING GUIDELINES OF CONVENTIONAL SYNTHETIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS
Kermond, A.
Robinson, P.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 2147 - 2148
[7] ADHERENCE TO BIOLOGIC AND CONVENTIONAL DISEASE MODIFYING ANTI-RHEUMATIC DRUGS IN PATIENTS WITH RHEUMATOID ARTHRITIS
Mishra, P.
VALUE IN HEALTH, 2018, 21 : S198 - S198
[8] PATIENTS' BELIEFS RELATING TO THE USE AND EFFICACY OF DISEASE MODIFYING ANTI-RHEUMATIC DRUGS
Goodacre, L. J.
Smith, J.
Goodacre, J. A.
RHEUMATOLOGY, 2002, 41 : 73 - 73
[9] Biologic and targeted synthetic disease-modifying anti-rheumatic drugs improve body composition in rheumatoid arthritis patients more than conventional synthetic disease-modifying anti-rheumatic drugs: Results from the PRESENT study
Tada, Masahiro
Matsumoto, Yoshinari
Koike, Tatsuya
Mamoto, Kenji
Nakamura, Tomoyuki
Anno, Shohei
Iida, Takahiro
Goto, Hitoshi
Hidaka, Noriaki
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2024, 27 (10)
[10] A Practical Approach to the Use of Conventional Synthetic, Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for the Treatment of Inflammatory Arthritis in Patients with a History of Malignancy
Peter K. K. Wong
Hanish Bagga
Claire Barrett
Geoff Chong
Patrick Hanrahan
Teja Kodali
Mona Marabani
H. Miles Prince
John Riordan
Phillip Swarbrick
Ray White
Laurel Young
Current Rheumatology Reports, 2018, 20

← 1 2 3 4 5 →